非小细胞肺癌胸部放疗联合免疫治疗研究进展

doi:10.3760/cma.j.cn113030-20211014-00405

摘要
图/表
参考文献(46)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要非小细胞肺癌(NSCLC)放疗联合免疫治疗,特别是联合PD-1/PD-L1免疫检查点抑制剂治疗,已成为近年来的研究焦点。探索放疗与免疫治疗的最优空间组合模式,实现各期患者最大限度的获益,是目前临床研究的方向之一。本文对放疗对肿瘤免疫环境的影响、各期NSCLC放疗联合免疫治疗进展以及存在的问题进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	许桐榛
	梁军

关键词 ：癌,非小细胞肺, 放射疗法, 免疫疗法, 研究进展

Abstract：Radiotherapy combined with immunotherapy for non-small cell lung cancer (NSCLC), especially with PD-1/PD-L1 immune checkpoint inhibitors, have fallen under the spotlight in recent years. How to explore the optimal combination modality of radiotherapy and immunotherapy to maximize the benefits for all-stage patients is one of the developing directions of clinical research. This article expounds the effect of radiotherapy on tumor immunology, research progress on radiotherapy combined with immunotherapy for various stages of NSCLC, and the problems existing in radiotherapy combined with immunotherapy.

Key words： Carcinoma, non-small-cell lung Radiotherapy Immunotherapy Research progress

收稿日期: 2021-10-14

基金资助:中国医学科学院肿瘤医院深圳医院院内课题(SZ2020MS004)

通讯作者: 梁军,Email:liang23400@163.com

引用本文:

许桐榛,梁军. 非小细胞肺癌胸部放疗联合免疫治疗研究进展[J]. 中华放射肿瘤学杂志, 2022, 31(6): 579-584.

Xu Tongzhen,Liang Jun. Research progress on radiotherapy combined with immunotherapy for non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 579-584.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20211014-00405 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I6/579

[1] Boustani J, Grapin M, Laurent PA, et al. The 6^th R of radiobiology:reactivation of anti-tumor immune response[J]. Cancers (Basel), 2019, 11(6) DOI:10.3390/cancers11060860.
[2] Wang Y, Liu ZG, Yuan H, et al. The reciprocity between radiotherapy and cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(6):1709-1717. DOI:10.1158/1078-0432. CCR-18-2581.
[3] Reynders K, Illidge T, Siva S, et al. The abscopal effect of local radiotherapy:using immunotherapy to make a rare event clinically relevant[J]. Cancer Treat Rev, 2015, 41(6):503-510. DOI:10.1016/j.ctrv.2015.03.011.
[4] Samstein R, Rimner A, Barker CA, et al. Combined immune checkpoint blockade and radiation therapy:timing and dose fractionation associated with greatest survival duration among over 750 treated patients[J]. Int J Radiat Oncol Biol Phys, 2017,99(2):S129-S130. DOI:10.1016/j.ijrobp.2017.06.303.
[5] Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer:A nonrandomized controlled trial[J]. JAMA Oncol, 2020, 6(6):848-855. DOI:10.1001/jamaoncol.2019.6731.
[6] Chang J Y. I-SABR phase Ⅱ randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC:Interim analysis adverse effects., ASCO Virtual Scientific Program, 2020[C]. Chicago, IL:American Society of Clinical Oncology, 2020.
[7] Kelly K. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer., ASCO Virtual Scientific Program, 2020[C]. Chicago, IL:American Society of Clinical Oncology, 2020.
[8] Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer[J]. N Engl J Med, 2018, 378(21):1976-1986. DOI:10.1056/NEJMoa1716078.
[9] Cascone T, William WN Jr, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer:the phase 2 randomized NEOSTAR trial[J]. Nat Med, 2021, 27(3):504-514. DOI:10.1038/s41591-020-01224-2.
[10] Besse B, Adam J, Cozic N, et al. 121SO-SC:Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial: [C].Ifema, Feria De Madrid: European Society for Medical Oncology, 2020.
[11] Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer:a single-centre, randomised phase 2 trial[J]. Lancet Oncol, 2021, 22(6):824-835. DOI:10.1016/S1470-2045(21)00149-2.
[12] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20):1919-1929. DOI:10.1056/NEJMoa1709937.
[13] Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer:hoosier cancer research network LUN 14-179[J]. Cancer, 2020, 126(19):4353-4361. DOI:10.1002/cncr.33083.
[14] Lin SH, Lin Y, Yao L, et al. Phase Ⅱ trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC[J]. J Thorac Oncol, 2020, 15(2):248-257. DOI:10.1016/j.jtho.2019.10.024.
[15] Sakaguchi T, Ito K, Furuhashi K, et al. Patients with unresectable stage Ⅲ non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria[J]. Respir Investig, 2019, 57(5):466-471. DOI:10.1016/j.resinv.2019.03.011.
[16] Hosoya K, Fujimoto D, Kawachi H, et al. Ineligibility for the PACIFIC trial in unresectable stage Ⅲ non-small cell lung cancer patients[J]. Cancer Chemother Pharmacol, 2019, 84(2):275-280. DOI:10.1007/s00280-019-03885-4.
[17] Jung HA, Noh JM, Sun JM, et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. Lung Cancer, 2020, 146:23-29. DOI:10.1016/j.lungcan.2020.05.035.
[18] Faehling M, Schumann C, Christopoulos P, et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC):real-world data on survival and safety from the german expanded-access program (EAP)[J]. Lung Cancer, 2020, 150:114-122. DOI:10.1016/j.lungcan.2020.10.006.
[19] Peters S, Felip E, Dafni U, et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage ⅢA-B NSCLC:results from the European thoracic oncology platform NICOLAS phase Ⅱ trial (European thoracic oncology platform 6-14)[J]. J Thorac Oncol, 2021, 16(2):278-288. DOI:10.1016/j.jtho.2020.10.129.
[20] Kogure Y, Oki M, Saka H. Sequential atezolizumab achieved remarkable efficacy after local radiotherapy in a patient with lung adenocarcinoma refractory to nivolumab[J]. J Thorac Oncol, 2019, 14(4):e74-e75. DOI:10.1016/j.jtho.2018.11.029.
[21] Lemmon C. A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage ⅢA non-small cell lung cancer., ASCO Virtual Scientific Program, 2020[C]. Chicago, IL:American Society of Clinical Oncology,2020.
[22] Ross HJ, Kozono DE, Urbanic JJ, et al. AFT-16:Phase Ⅱ trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage Ⅲ non-small cell lung cancer (NSCLC)[J]. J Clinic Oncol, 2020,38(15_suppl):9045. DOI:10.1200/JCO.2020.38.15_suppl.9045.
[23] Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage Ⅲ non-small cell lung cancer:the phase 2 KEYNOTE-799 nonrandomized trial[J]. JAMA Oncol, 2021, DOI:10.1001/jamaoncol.2021.2301.
[24] Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer:a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895-903. DOI:10.1016/S1470-2045(17)30380-7.
[25] Ratnayake G, Shanker M, Roberts K, et al. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2020, 16(1):56-62. DOI:10.1111/ajco.13242.
[26] Lesueur P, Escande A, Thariat J, et al. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer:A multicentric retrospective study from the GFPC[J]. Cancer Med, 2018, 7(11):5505-5513. DOI:10.1002/cam4.1825.
[27] Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer:A phase 2 trial[J]. JAMA Oncol, 2019, 5(9):1283-1290. DOI:10.1001/jamaoncol.2019.1449.
[28] Theelen W, Peulen H, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer:results of the pembro-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282. DOI:10.1001/jamaoncol.2019.1478.
[29] Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer:a randomized phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2) DOI:10.1136/jitc-2020-001001.
[30] Theelen W, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5):467-475. DOI:10.1016/S2213-2600(20)30391-X.
[31] Fiorica F, Belluomini L, Stefanelli A, et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients:efficacy and safety of combination[J]. Am J Clin Oncol, 2018, 41(11):1101-1105. DOI:10.1097/COC.00000000000004 28.
[32] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135. DOI:10.1056/NEJMoa1504627.
[33] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639. DOI:10.1056/NEJMoa1507643.
[34] Miyamoto S, Nomura R, Sato K, et al. Nivolumab and stereotactic radiation therapy for the treatment of patients with stage ⅠV non-small-cell lung cancer[J]. Jpn J Clin Oncol, 2019, 49(2):160-164. DOI:10.1093/jjco/hyy171.
[35] Patel JD. Randomized phase I trial to evaluate concurrent or sequential ipilimumab/nivolumab, and stereotactic body radiotherapy in patients with stage IV non-small cell lung cancer (COSINR study), ASCO Virtual Scientific Program, 2020[C]. Chicago, IL:American Society of Clinical Oncology, 2020.
[36] Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL):a phase 3, open-label, randomised controlled trial[J]. Lancet Oncol, 2019, 20(4):494-503. DOI:10.1016/S1470-2045(18)30896-9.
[37] Theelen W, Peulen H, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer:results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282. DOI:10.1001/jamaoncol.2019.1478.
[38] Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer:a randomized phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2) DOI:10.1136/jitc-2020-001001.
[39] Antonia SJ, Balmanoukian A, Brahmer J, et al. Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC[J]. J Thorac Oncol, 2019, 14(10):1794-1806. DOI:10.1016/j.jtho.2019.06.010.
[40] Fehrenbacher L, von Pawel J, Park K, et al. Updated efficacy analysis including secondary population results for OAK:a randomized phase Ⅲ study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer[J]. J Thorac Oncol, 2018, 13(8):1156-1170. DOI:10.1016/j.jtho.2018.04.039.
[41] Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage Ⅲ non-small cell lung cancer:hoosier cancer research network LUN 14-179[J]. Cancer, 2020, 126(19):4353-4361. DOI:10.1002/cncr.33083.
[42] Haikerwal SJ, Hagekyriakou J, MacManus M, et al. Building immunity to cancer with radiation therapy[J]. Cancer Lett, 2015, 368(2):198-208. DOI:10.1016/j.canlet.2015.01.009.
[43] Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab:results from the phase I KEYNOTE-001 study[J]. J Clin Oncol, 2019, 37(28):2518-2527. DOI:10.1200/JCO.19.00934.
[44] Ready N, Hellmann MD, Awad MM, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568):outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers[J]. J Clin Oncol, 2019, 37(12):992-1000. DOI:10.1200/JCO.18.01042.
[45] McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(1):46-54. DOI:10.1001/jamaoncol.2015.3638.
[46] Garassino MC, Rodríguez-Abreu D, Gadgeel S, et al. OA04.06 evaluation of TMB in KEYNOTE-189:pembrolizumab plus chemotherapy vs. placebo plus chemotherapy for nonsquamous NSCLC[J]. J Thorac Oncol, 2019,14(10):S216-S217. DOI:10.1016/j.jtho.2019.08.427.